Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.

Glutamatergic Modulators for Major Depression from Theory to Clinical Use

Open access
McIntyre, Roger S., Jain, Rakesh · 2024 · CNS Drugs

Abstract

Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is characterized by depressed mood and anhedonia. MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates. In the past 2 decades, a promising target emerged to improve patient outcomes in depression treatment: glutamatergic signaling. This narrative review provides a high-level overview of glutamate signaling in synaptogenesis and neural plasticity and the implications of glutamate dysregulation in depression. Based on this preclinical evidence implicating glutamate in depression and the rapid improvement of depression with ketamine treatment in a proof-of-concept trial, a range of N-methyl-d-aspartate (NMDA)-targeted therapies have been investigated. While an array of treatments has been investigated in registered phase 2 or 3 clinical trials, the development of most of these agents has been discontinued. Multiple glutamate-targeted antidepressants are actively in development, and two are approved. Nasal administration of esketamine (Spravato®) was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant depression and in 2020 for adults with MDD with acute suicidal ideation or behavior. Oral combination dextromethorphan–bupropion (AXS-05, Auvelity® extended-release tablet) was FDA approved in 2022 for the treatment of MDD in adults. These approvals bolster the importance of glutamate in depression and represent an exciting breakthrough in contemporary psychiatry, providing new avenues of treatment for patients as first-line therapy or with either poor response or unacceptable side effects to monoaminergic antidepressants. Major depressive disorder (MDD) is a common disease defined by sadness and a loss of interest or pleasure in activities. Depression treatments include therapy and antidepressant medication. Most available antidepressants affect the same types of chemicals that communicate in the brain (neurotransmitters) called monoamines. Unfortunately, these medicines can take weeks to work for some people and many still have depression symptoms with treatment. To provide more treatment options, new medicines have been studied that impact a different neurotransmitter in the brain, that is, glutamate. Glutamate, the most abundant neurotransmitter, is important for the growth of new brain cell connections, and there are changes in glutamate in people with depression versus people without depression. In 2000, the first small study in people showed that ketamine, a medicine targeting glutamate, quickly improved depression symptoms. Safety risks, including dissociation and sedation, require supervised administration and management guidance. Since 2000, about 20 glutamate-targeted medicines have been tested in human clinical trials. Two of these are approved as antidepressants. The medicine esketamine, which is inhaled up the nose at a clinic under medical supervision, is approved for the adjunctive treatment of people with MDD whose symptoms do not improve with other treatments or who have suicidal thoughts or actions (brand name Spravato®). The combination medicine dextromethorphan–bupropion is a swallowed tablet taken twice daily that is an approved monotherapy to treat adults with MDD (brand name Auvelity®). The approval of these drugs helps show the importance of glutamate in depression and provides more options for people with depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-024-01114-y

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Glutamate signaling in neuroplasticity and synaptogenesis. Akt protein kinase B, AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, BDNF brain-derived neurotrophic factor, EAAT excitatory amino acid transporter, EF2 eukaryotic elongation factor 2, ERK extracellular signal-regulated kinases, Gln glutamine, Glu glutamate, mGluR metabotropic glutamate receptor, mTOR mammalian target of rapamycin, NMDAR N-methyl-d-aspartate receptor, P phosphorylated, TrkB tropomyosin receptor kinase B, vGLUT vesicular glutamate transporter. Modified from Lener et al. 2017 [162] and Henter et al. 2021 [14]. Figure illustration elements modified from Servier Medical Art (2022) by Servier (https://smart.servier.com, used under a Creative Commons Attribution 4.0 License)
Fig. 1 Glutamate signaling in neuroplasticity and synaptogenesis. Akt protein kinase B, AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, BDNF brain-derived neurotrophic factor, EAAT excitatory amino acid transporter, EF2 eukaryotic elongation factor 2, ERK extracellular signal-regulated kinases, Gln glutamine, Glu glutamate, mGluR metabotropic glutamate receptor, mTOR mammalian target of rapamycin, NMDAR N-methyl-d-aspartate receptor, P phosphorylated, TrkB tropomyosin receptor kinase B, vGLUT vesicular glutamate transporter. Modified from Lener et al. 2017 [162] and Henter et al. 2021 [14]. Figure illustration elements modified from Servier Medical Art (2022) by Servier (https://smart.servier.com, used under a Creative Commons Attribution 4.0 License)CC BY-NC · PubMed Central
Fig. 2 Timeline of registered trials of glutamate-targeted drugs for treatment of depressiona. aFigure includes phase 2, 3, and 4 trials registered on ClinicalTrials.gov for the treatment of MDD or TRD as detailed in Online Resource 1, Supplementary Table 1. bThe first placebo-controlled, double-blind trial of ketamine in seven people with depression, conducted in 2000, was not registered on ClinicalTrials.gov [64]. cIntranasal esketamine is approved by the FDA, TPD, EMA, and TGA as an adjunctive treatment for TRD and/or for MDD with suicidal ideation/behavior or psychiatric emergency. dAXS-05 is approved to treat MDD in adults by the FDA. EMA European Medicines Agency, FDA US Food and Drug Administration, MDD major depressive disorder, NMDA N-methyl d-aspartate, TGA Australia’s Therapeutic Goods Administration, TPD Canada’s Therapeutic Products Directorate, TRD treatment-resistant depression
Fig. 2 Timeline of registered trials of glutamate-targeted drugs for treatment of depressiona. aFigure includes phase 2, 3, and 4 trials registered on ClinicalTrials.gov for the treatment of MDD or TRD as detailed in Online Resource 1, Supplementary Table 1. bThe first placebo-controlled, double-blind trial of ketamine in seven people with depression, conducted in 2000, was not registered on ClinicalTrials.gov [64]. cIntranasal esketamine is approved by the FDA, TPD, EMA, and TGA as an adjunctive treatment for TRD and/or for MDD with suicidal ideation/behavior or psychiatric emergency. dAXS-05 is approved to treat MDD in adults by the FDA. EMA European Medicines Agency, FDA US Food and Drug Administration, MDD major depressive disorder, NMDA N-methyl d-aspartate, TGA Australia’s Therapeutic Goods Administration, TPD Canada’s Therapeutic Products Directorate, TRD treatment-resistant depressionCC BY-NC · PubMed Central
Fig. 3 Response and remission rates with adjunctive intranasal esketamine in TRANSFORM-2 triala,b. aTRANSFORM-2 (NCT02418585) investigated adjunctive flexibly dosed intranasal esketamine versus adjunctive placebo with a newly initiated oral SNRI or SSRI antidepressant, in patients with TRD in a 28-day double-blind treatment phase. bPercentages shown are the proportion of patients remaining at visit [127]. ADT antidepressant, IN intranasal, MADRS Montgomery-Åsberg Depression Rating Scale, SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TRD treatment-resistant depression, NR not reported
Fig. 3 Response and remission rates with adjunctive intranasal esketamine in TRANSFORM-2 triala,b. aTRANSFORM-2 (NCT02418585) investigated adjunctive flexibly dosed intranasal esketamine versus adjunctive placebo with a newly initiated oral SNRI or SSRI antidepressant, in patients with TRD in a 28-day double-blind treatment phase. bPercentages shown are the proportion of patients remaining at visit [127]. ADT antidepressant, IN intranasal, MADRS Montgomery-Åsberg Depression Rating Scale, SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TRD treatment-resistant depression, NR not reportedCC BY-NC · PubMed Central
Fig. 4 Antidepressant mechanisms of sigma-1 receptorsa. aActivated sigma-1 receptors may: translocate from the ER to ion channels, GPCR, or NMDAR at the cell membrane to modulate receptor activity; stabilize IP3R to maintain Ca2+ flow and ATP production; and modulate ER stress to enable downstream BDNF expression. ASIC1a acid-sensing ion channel, ATP adenosine triphosphate, BDNF brain-derived neurotrophic factor, CaMKII calmodulin-dependent protein kinase II, ER endoplasmic reticulum, ERK extracellular signal-regulated kinase, GPCR G-protein coupled receptor, IP3R inositol 1,4,5-trisphosphate receptor, IRE1 inositol-requiring enzyme 1, mTOR mammalian target of rapamycin, NMDAR N-methyl-d-aspartate receptor, P phosphorylated, XBP1 X-box-binding protein 1. Figure illustration elements modified from Servier Medical Art (2022) by Servier (https://smart.servier.com, under a Creative Commons Attribution 4.0 License)
Fig. 4 Antidepressant mechanisms of sigma-1 receptorsa. aActivated sigma-1 receptors may: translocate from the ER to ion channels, GPCR, or NMDAR at the cell membrane to modulate receptor activity; stabilize IP3R to maintain Ca2+ flow and ATP production; and modulate ER stress to enable downstream BDNF expression. ASIC1a acid-sensing ion channel, ATP adenosine triphosphate, BDNF brain-derived neurotrophic factor, CaMKII calmodulin-dependent protein kinase II, ER endoplasmic reticulum, ERK extracellular signal-regulated kinase, GPCR G-protein coupled receptor, IP3R inositol 1,4,5-trisphosphate receptor, IRE1 inositol-requiring enzyme 1, mTOR mammalian target of rapamycin, NMDAR N-methyl-d-aspartate receptor, P phosphorylated, XBP1 X-box-binding protein 1. Figure illustration elements modified from Servier Medical Art (2022) by Servier (https://smart.servier.com, under a Creative Commons Attribution 4.0 License)CC BY-NC · PubMed Central
Fig. 5 Response and remission rates with oral AXS-05 in GEMINI trial. ***P < 0.001 versus control; analyzed via χ2 test. a GEMINI (NCT04019704) investigated AXS-05 versus placebo in patients with MDD for a 6-week double-blind treatment period. MADRS Montgomery-Åsberg Depression Rating Scale, MDD major depressive disorder, PO oral
Fig. 5 Response and remission rates with oral AXS-05 in GEMINI trial. ***P < 0.001 versus control; analyzed via χ2 test. a GEMINI (NCT04019704) investigated AXS-05 versus placebo in patients with MDD for a 6-week double-blind treatment period. MADRS Montgomery-Åsberg Depression Rating Scale, MDD major depressive disorder, PO oralCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 133 references

Research works printed but not linked: 2

  1. Réus GZ, Quevedo J, Lúcia S, Rodrigues A. Mtor signaling in the neuropathophysiology of depression: current evidence. J Recept Ligand Channel Res. 2015;65:78.
  2. Paterson B, Fraser H, Wang C, et al. A randomized, double-blind, placebo-controlled, sequential parallel study of cerc-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. National Network of Depression Centers Annual Conference; Ann Arbor, MI. 2015.

Cited by

See all 69

Metadata

Authors
McIntyre, R. S., & Jain, R.
Affiliations
  • University of Toronto (CA)
  • Texas Tech University (US)
Corresponding author
Jain, Rakesh
Venue
CNS Drugs
Published
2024-08-16
Volume
38
Issue
11
Pages
869-890
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W4401654837
Cited by
69
References
133
Citations by year
2026: 33 · 2025: 34 · 2024: 2
FWCI
4.32
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Axsome Therapeutics., Inc.
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
major depressive disorder, glutamate signaling, NMDA receptor, ketamine, esketamine, treatment-resistant depression, synaptogenesis, neuroplasticity, antidepressant drug development, anhedonia, suicidal ideation, intranasal administration, drug safety and tolerability
MeSH terms
Animals, Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Excitatory Amino Acid Agents, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glutamatergic Modulators for Major Depression from Theory to Clinical Use. https://app.cochat.ai/papers/10.1007/s40263-024-01114-y
The paper
McIntyre, R. S., & Jain, R. (2024). Glutamatergic Modulators for Major Depression from Theory to Clinical Use. CNS Drugs. https://doi.org/10.1007/s40263-024-01114-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.